Xenon Pharmaceuticals Inc.

9 trials 6 recruiting Commercial sponsor

Filter these 9 trials by condition, phase, country and more.

Open in Search →

9 Registered trials

6 Recruiting

2 Completed trials

18 Countries active

1 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 8 Phase II: 1

Oversight events:

2 serious breaches across 2 trials

View oversight register →

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Generalised tonic-clonic seizure 1

Top IMPs

All trials

9 total

An Open-label Study of Azetukalner in Bipolar I or II Depression Pending

2025-522872-10-00 Phase III 4 countries AZETUKALNER
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) - X-CE… Recruiting

2025-522775-29-00 Phase III 4 countries AZETUKALNER
An Open-label Study of Azetukalner in Major Depressive Disorder Recruiting

2025-523618-10-00 Phase III 6 countries AZETUKALNER
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder Recruiting

2025-523202-32-00 Phase III 7 countries AZETUKALNER
A randomized study of XEN1101 versus placebo in Primary Generalised Tonic Clonic Seizures (X-ACKT) Recruiting

2022-502286-16-00 Phase III 12 countries AZETUKALNER
An Open-label Study of XEN1101 in Epilepsy Recruiting

2022-502282-24-00 Phase III 16 countries AZETUKALNER
Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) Recruiting

2022-502281-25-00 Phase III 14 countries AZETUKALNER
A multicenter study to evaluate the safety, tolerability and efficacy of XEN1101 as additional therapy to standard treatment in focal epilep… Ended

2023-508681-15-00 Phase II 3 countries AZETUKALNER
Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE2) Ended

2022-502000-73-00 Phase III 9 countries AZETUKALNER

Showing 1–9 of 9 trials

← All sponsors A–Z